Cardiovascular biomarkers in groups of established smokers after a decade of smoking

Basic and Clinical Pharmacology and Toxicology

Volumn 104, Issue 4, 2009, Pages 322-328

  Calapai, Gioacchino ^a   Caputi, Achille P ^a,b   Mannucci, Carmen ^a   Russo, Giuseppina A ^a   Gregg, Evan ^c   Puntoni, Riccardo ^c   Lowe, Frazer ^c   McEwan, Mike ^c   Bassi, Antonella ^d   Morandi, Stefania ^d   Nunziata, Alfredo ^d  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c BRITISH AMERICAN TOBACCO   (United Kingdom)

^d British American Tobacco Italia SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; 2,3 DINORTHROMBOXANE B2; CARBON MONOXIDE; HEMOGLOBIN; NICOTINE;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE MARKER; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; NEUTROPHIL COUNT; OXIDATIVE STRESS; PRIORITY JOURNAL; SMOKING; URINALYSIS; VASCULAR DISEASE;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HEMOGLOBINS; HUMANS; LEUKOCYTE COUNT; MALE; RISK FACTORS; SEX FACTORS; SMOKING; TARS; THROMBOXANE B2; THROMBOXANES; YOUNG ADULT;

EID: 62549101274     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00361.x     Document Type: Article

References (39)

1. Burns D. Epidemiology of smoking-induced cardiovascular disease. Prog Cardiovasc Dis 2003 46 : 11 29.
2. International Agency for Research on Cancer (IARC). Tobacco: A Major International Health Hazard. IARC, Lyon, 1986.
3. Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: the science base for tobacco harm reduction - executive summary. Tob Control 2001 10 : 189 95.
4. Wilson PW. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. Circulation 2004 110 : 568 71.
5. Gregg EO, Fisher A-L, Lowe F, McEwan M, Massey ED. An approach to the validation of biomarkers of harm for use in a tobacco context. Regulatory Toxicol Pharmacol 2006 44 : 262 7.
6. Hatsukami DK, Benowitz NL, Rennard SI, Oncken C, Hecht SS. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res 2006 8 : 600 22.
7. Hatsukami DK, Hecht SS, Hennrikus DJ, Joseph AM, Pentel PR. Biomarkers of tobacco exposure or harm: application to clinical and epidemiological studies. 25-26 October 2001, Minneapolis, Minnesota. Nicotine Tob Res 2003 5 : 387 96.
8. Javors MA, Hatch JP, Lamb RJ. Cut-off levels for breath carbon monoxide as a marker for cigarette smoking. Addiction 2005 100 : 159 67.
9. Eberhardt M, Powell A, Bonfante G, Rupp V, Guarnaccia JR, Heller M et al. Noninvasive measurement of carbon monoxide levels in ED patients with headache. J Med Toxicol 2006 2 : 89 92.
10. Townsend CL, Maynard RL. Effects on health of prolonged exposure to low concentrations of carbon monoxide. Occup Environ Med 2002 59 : 708 11.
11. Leone A. Biochemical markers of cardiovascular damage from tobacco smoke. Curr Pharm Des 2005 11 : 2199 208.
12. Whincup P, Papacosta O, Lennon L, Haines A. Carboxyhaemoglobin levels and their determinants in older British men. BMC Public Health 2006 6 : 189.
13. Aronow WS, Cassidy J. Effect of carbon monoxide on maximal treadmill exercise. A study in normal persons. Ann Intern Med 1975 83 : 496 99.
14. Borland C, Chamberlain A, Higenbottam T, Shipley M, Rose G. Carbon monoxide yield of cigarettes and its relation to cardiorespiratory disease. Br Med J (Clin Res Ed) 1983 287 : 1583 86.
15. Lavi S, Prasad A, Yang EH, Mathew V, Simari RD, Rihal CS et al. Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation 2007 115 : 2621 7.
16. Brown DW, Ford ES, Giles WH, Croft JB, Balluz LS, Mokdad AH. Associations between white blood cell count and risk for cerebrovascular disease mortality: NHANES II Mortality Study, 1976-1992. Ann Epidemiol 2004 14 : 425 30.
17. Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler Thromb Vasc Biol 2005 25 : 658 70.
18. Kawaguchi H, Mori T, Kawano T, Kono S, Sasaki J, Arakawa K. Band neutrophil count and the presence and severity of coronary atherosclerosis. Am Heart J 1996 132 : 9 12.
19. Inoue O, Seiji K, Takahashi M, Kudo K, Nakatsuka H, Watanabe T et al. Subtle increase in leukocyte counts in association with drinking and smoking habits. Int Arch Occup Environ Health 1995 66 : 383 88.
20. Freedman DS, Flanders WD, Barboriak JJ, Malarcher AM, Gates L. Cigarette smoking and leukocyte subpopulations in men. Ann Epidemiol 1996 6 : 299 306.
21. Geffken D, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol 2001 153 : 242 50.
22. Jensen EJ, Pedersen B, Frederiksen R, Dahl R. Prospective study on the effect of smoking and nicotine substitution on leucocyte blood counts and relation between blood leucocytes and lung function. Thorax 1998 53 : 784 89.
23. Dautzenberg MD. Smoking-related biological alterations in women: a way to start talking about smoking. The internist's point a view: the clinical biologist's point of view. J Gynecol Obstet Biol Reprod (Paris) 2005 34 : 38279 91.
24. Skjelbakken T, Dahl IM, Wilsgaard T, Langbakk B, Løchen ML. Changes in haemoglobin levels according to changes in body mass index and smoking habits, a 20-year follow-up of a male cohort: the Tromsø Study 1974-1995. Eur J Epidemiol 2006 21 : 493 99.
25. Salive ME, Cornoni-Huntley J, Guralnik JM, Phillips CL, Wallace RB, Ostfeld AM et al. Anemia and hemoglobin levels in older persons: relationship with age, gender, and health status. J Am Geriatr Soc 1992 40 : 489 96.
26. Bentley DP. Anaemia and chronic disease. Clin Haematol 1982 11 : 465 79.
27. Knottnerus JA, Swaen GM, Slangen JJ, Volovics A, Durinck J. Haematologic parameters as risk factors for cardiac infarction, in an occupational health care setting. J Clin Epidemiol 1988 41 : 67 74.
28. Chonchol M, Nielson C. Hemoglobin levels and coronary artery disease. Am Heart J 2008 155 : 494 8.
29. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest 2007 131 : 1557 66.
30. Morrow J, Hill K, Burk R, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase free radical catalysed mechanism. Proc Natl Acad Sci USA 1990 87 : 9383 7.
31. Helmersson J, Larsson A, Vessby B, Basu S. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2α), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis 2005 181 : 201 7.
32. Fernandez ML, Webb D. The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. J Am Coll Nutr 2008 27 : 1 5.
33. Császár A. Hypertriglyceridemia, the coronary heart disease risk marker 'solved'. Acta Physiol Hung 2005 92 : 109 20.
34. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997 17 : 2309 15.
35. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987 76 : 6 14.
36. Zhang W, Zhang Y, Edvinsson L, Xu CB. Up-regulation of thromboxane A2 receptor expression by lipid soluble smoking particles through post-transcriptional mechanisms. Atherosclerosis 2008 196 : 608 16.
37. Patrono C, Davi G, Ciabattoni G. Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. Trends Cardiovasc Med 1992 2 : 15 20.
38. Ingall TJ, Homer D, Baker HL Jr., Kottke BA, O'Fallon WM, Whisnant JP. Predictors of intracranial carotid artery atherosclerosis. Duration of cigarette smoking and hypertension are more powerful than serum lipid levels. Arch Neurol 1991 48 : 687 91.
39. Bolego C, Poli A, Paoletti R. Smoking and gender. Cardiovasc Res 2002 53 : 568 76.